Structure Therapeutics Inc (GPCR)
33.44
+3.34
(+11.10%)
USD |
NASDAQ |
Nov 22, 16:00
33.44
0.00 (0.00%)
After-Hours: 20:00
Structure Therapeutics Research and Development Expense (Quarterly): 32.60M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 32.60M |
| June 30, 2024 | 22.05M |
| March 31, 2024 | 20.68M |
| December 31, 2023 | 20.04M |
| September 30, 2023 | 17.52M |
| June 30, 2023 | 19.41M |
| Date | Value |
|---|---|
| March 31, 2023 | 13.14M |
| December 31, 2022 | 8.36M |
| September 30, 2022 | 9.16M |
| June 30, 2022 | 10.18M |
| March 31, 2022 | 8.492M |
| December 31, 2021 | 9.907M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.36M
Minimum
Dec 2022
32.60M
Maximum
Sep 2024
15.96M
Average
15.32M
Median
Research and Development Expense (Quarterly) Benchmarks
| Viking Therapeutics Inc | 22.78M |
| Eli Lilly and Co | 2.734B |
| Novo Nordisk AS | 1.398B |
| Pfizer Inc | 2.598B |
| Amgen Inc | 1.45B |